跳至主要内容
临床试验/NCT01610362
NCT01610362已完成不适用

Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response

Queen Saovabha Memorial Institute2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2012年6月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
50
试验地点
2
主要终点
Rabies Neutralizing antibody titers in volunteers who receive HRIG 40 IU/kg

研究概览

简要总结

Dosage of rabies immune globulin was calculated from the victim's body weight, then the amount of rabies immune globulin would be injected as much as possible to all of the wounds. Increase dosage of rabies immune globulin was needed in situation of multiple severe bite-wounds especially among children whose had lower body weight than adults. Our study would be conducted in order to determine whether the increase dosage of rabies immune globulin would interfere with the protective antibody levels against rabies.

详细描述

  • Controlled trial study.
  • All 50 volunteers who had never had rabies immunization would be enrolled and designated into 2 groups.

group 1 : 15 Healthy volunteers age 18 - 60 yr who were attacked by mammals, possible exposed to rabies and had WHO category III exposure, all receive standard post - exposure rabies treatment with 5-dose intramuscular rabies vaccine on day 0,3,7,14,28 and 20 IU/kg of human rabies immune globulin (HRIG).

group 2 : 35 Healthy volunteers age 18 - 60 yr receive 5-dose intramuscular rabies vaccine on day 0,3,7,14,28 and 40 IU/kg of human rabies immune globulin (HRIG).

5 cc - Blood would be drawn from all volunteers before vaccination and on day 14, 28 and 90 for rabies neutralizing antibody titers (RNab).

The GMTs of RNab among both groups would be analyzed and compared.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • healthy volunteers age 18-60 years.

排除标准

  • received prior rabies immunization
  • pregnancy
  • immunocompromised conditions

研究组 & 干预措施

5-dose IM rabies vaccines, HRIG 20 IU/kg

Active Comparator

Rabies exposed victims, 5-dose IM rabies vaccine, HRIG 20 IU/kg

干预措施: Human Rabies Immune Globulin (Biological)

5-dose IM rabies vaccines, HRIG 40 IU/kg

Experimental

Healthy volunteers, 5-dose IM rabies vaccine, HRIG 40 IU/kg

干预措施: Human Rabies Immune Globulin (Biological)

结局指标

主要结局

Rabies Neutralizing antibody titers in volunteers who receive HRIG 40 IU/kg

时间窗: Change from baseline of Rabies Neutralizing Antibody Titers at 3 - month period

Rabies Neutralizing antibody titers in volunteers who receive HRIG 40 IU/kg would be determined on day 0,14, 28 and 90. Rnab titers above 0.5 IU/ml would be considered as protective levels as WHO recommendation.

次要结局

  • Number of participants who have Rabies Neutralizing antibody titers above protective levels.(Number of participants who have Rabies Neutralizing antibody titers above protective levels at 3-month period..)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Suda Sibunruang

Principal investigator

Queen Saovabha Memorial Institute

研究点 (2)

Loading locations...

相似试验

尚未招募
不适用
To determine the exact dose of rabies immunoglobulin for local wound management of animal bite in children and adolescents.
CTRI/2021/01/030409Department of Pediatrics Maulana Azad Medical College
进行中(未招募)
1 期
Phase II multicenter trial regarding pharmacokinetics, safety and efficacy of continuous infusion of IGF-I to premature infants to prevent the onset of Retinopathy of PrematurityRetinopathy of Prematurity (ROP)MedDRA version: 17.1Level: SOCClassification code 10015919Term: Eye disordersSystem Organ Class: 10015919 - Eye disorders
EUCTR2007-007872-40-SEPremacure AB, A member of the Shire Group of Companies121
进行中(未招募)
1 期
Phase II multicenter trial regarding pharmacokinetics, safety and efficacy of continuous infusion of IGF-I to premature infants to prevent the onset of Retinopathy of PrematurityRetinopathy of Prematurity (ROP)MedDRA version: 18.0Level: SOCClassification code 10015919Term: Eye disordersSystem Organ Class: 10015919 - Eye disorders
EUCTR2007-007872-40-PLPremacure AB, A member of the Shire Group of Companies120
进行中(未招募)
1 期
Phase II multicenter trial regarding pharmacokinetics, safety and efficacy of continuous infusion of IGF-I to premature infants to prevent the onset of Retinopathy of Prematurity
EUCTR2007-007872-40-GBPremacure AB, A member of the Shire Group of Companies121
已完成
2 期
Determination of the rhIGF-I/rhIGFBP-3 Dose; Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal SErum IGF-I Levels within Physiological Levels in Premature Infants, to prevent Retinopathy of Prematurity;A Phase II, Randomized Controlled, Assessor-Blind, Dose-Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Studypremature retinopathyabnormal vasculair grow in the retina10047060
NL-OMON42210MediServ10